Work

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center

Year: 2015

Type: article

Study design: Observational Study

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2015.12.008

Authors: Vinayak Muralidhar, Meredith M. Regan, Lillian Werner, Mari Nakabayashi, Carolyn P. Evan, Joaquim Bellmunt, Toni K. Choueiri, Aymen A. Elfiky, Lauren C. Harshman, Rana R. McKay, Mark M. Pomerantz, Christopher J. Sweeney, Mary-Ellen Taplin, Philip W. Kantoff, Paul L. Nguyen

Institutions: Harvard University, Harvard–MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center

Language: English

Topic: Prostate Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Prostate Cancer Foundation, Pfizer, AstraZeneca, National Comprehensive Cancer Network, Astellas Pharma, Genentech, Abbott Diagnostics, National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2211222341

FWCI: 1.426

Cites: 22

Cited by: 12

Related to: 10